Good morning.
Interesting link with all the news registered
at the annual ASCO-GU meeting held this week of February.
Cheers
Annual summary ASCO-GU February-2020 - Advanced Prostate...
Annual summary ASCO-GU February-2020
Written by
fco1969
To view profiles and participate in discussions please or .
Not what you're looking for?
You may also like...
Abiraterone + Olaparib: ASCO GU 2024 Highlights: BRCAAway Trial
"Highlighting the trial's results, he notes the combination therapy significantly extended median...
ARASENS: Darolutamide + ADT + Docetaxel may become new SOC for mHSPC - from ASCO GU Symposium 2022
Dr. Matthew R Smith of Mass Gen. CC, reported significant overall survival from 3 ARASENS trial...
Holy Cow!....Indomethacin + Xtandi
Indo can block resistance to Enza and Xtandi and the combo kills cancer cells...I just got my Doc...
FDA Approves Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Other triple therapy approved by the FDA. The article has the basic results of the ARASENS trial....
Resistant to Zytiga, Xtandi and Chemo? Here is a promising trial.
At the recent ASCO GU 2022 conference the results of the CYPIDES trial were presented. This trial...
Related Posts
- Examining Prostate Cancer Survival Outcomes by Patient Age and Treatment Type in Patients with mHSPC
- ASCO GU 2024 abstracts
- Treatment Considerations for Prostate Cancer Progressing After Combination Therapy for mCSPC
- Lu 177 PSMA vs Cabazitaxel (Jevtana) in patients with mCRPC previously treated with Docetaxel and with a progressing PSA with values >/=20.
Join ASCO as a Patient Advocate for Free
